INT22212

From wiki-pain
Revision as of 15:34, 23 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.76
First Reported 1987
Last Reported 2010
Negated 5
Speculated 2
Reported most in Body
Documents 34
Total Number 39
Disease Relevance 10.11
Pain Relevance 2.77

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (CYP1A1) mitochondrion (CYP1A1) small molecule metabolic process (CYP1A1)
oxidoreductase activity (CYP1A1) endoplasmic reticulum (CYP1A1) enzyme binding (CYP1A1)
Anatomy Link Frequency
1A2 3
alveolar macrophages 3
hearts 3
liver 2
Caco-2 2
CYP1A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
alcohol 13 100.00 Very High Very High Very High
lidocaine 16 99.12 Very High Very High Very High
endometriosis 20 98.28 Very High Very High Very High
Paracetamol 11 93.80 High High
Morphine 2 93.32 High High
pain pelvic 5 93.28 High High
Versed 20 93.20 High High
Inflammation 37 93.12 High High
Codeine 5 92.80 High High
Dextromethorphan 1 92.28 High High
Disease Link Frequency Relevance Heat
Nicotine Addiction 553 99.96 Very High Very High Very High
Endometriosis (extended) 25 98.28 Very High Very High Very High
Cancer 205 97.96 Very High Very High Very High
Disease 214 97.00 Very High Very High Very High
Prostate Cancer 112 94.16 High High
Reprotox - General 3 5 93.28 High High
INFLAMMATION 38 93.12 High High
Frailty 20 92.56 High High
Myocardial Infarction 36 91.84 High High
Stress 168 91.56 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Effect of TCDD exposure on CYP1A1 and CYP1B1 expression in explant cultures of human endometrium.
Gene_expression (expression) of CYP1A1 in endometrium
1) Confidence 0.76 Published 2001 Journal Toxicol. Sci. Section Title Doc Link 11452143 Disease Relevance 0.42 Pain Relevance 0.20
The present study characterizes a human endometrial explant culture model for studying the direct effects of TCDD exposure by assessing the expression of CYP1A1 and CYP1B1 mRNA (Northern blotting), protein (Western blotting), and activity (7-ethoxyresorufin-O-deethylase; EROD) in explants cultured with and without TCDD.
Gene_expression (expression) of CYP1A1
2) Confidence 0.76 Published 2001 Journal Toxicol. Sci. Section Abstract Doc Link 11452143 Disease Relevance 0.41 Pain Relevance 0.20
The expression of CYP1A1 and CYP1B1 mRNA was greatest with 10 nM TCDD and increased up to 72 h after initial exposure.
Gene_expression (expression) of CYP1A1
3) Confidence 0.76 Published 2001 Journal Toxicol. Sci. Section Abstract Doc Link 11452143 Disease Relevance 0.42 Pain Relevance 0.22
A high-performance liquid chromatography method was developed to assay N-desmethylclomipramine, 8-hydroxyclomipramine, 2-hydroxyclomipramine, 8-hydroxydesmethhylclomipramine, didesmethylclomipramine and 2-hydroxydesmethylclomipramine formed by microsomes prepared from human liver and yeast expressing human CYP1A1, 1A2, 2C8, 2C9, 2C18, 2C19, 2D6 and 3A4.
Gene_expression (expressing) of CYP1A1 in 1A2
4) Confidence 0.75 Published 1996 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8667235 Disease Relevance 0 Pain Relevance 0
The upregulation of CYP1A1 and CYP1B1 expression by extract and purified cycloartanes cannot be explained by AhR binding.
Gene_expression (expression) of CYP1A1
5) Confidence 0.72 Published 2007 Journal BMC Pharmacol Section Body Doc Link PMC2194763 Disease Relevance 0.19 Pain Relevance 0
Although the cycloartane-type triterpenoids do not satisfy these structural requirements, gene expression of CYP1A1 was not only induced in our experiments by black cohosh extract but also by the cycloartane aglycons (5.0 ± 1.7 fold, p < 0.01 and 12.2 ± 3.4 fold, p < 0.01) and, to a lower but statistically significant extent, by actein (2.1 ± 0.8, p < 0.05 and 2.0 ± 0.2, p < 0.01).
Gene_expression (expression) of CYP1A1
6) Confidence 0.72 Published 2007 Journal BMC Pharmacol Section Body Doc Link PMC2194763 Disease Relevance 0.05 Pain Relevance 0
The compound was not metabolized by human CYP1A1 or 1A2 heterologously expressed in yeast and its rate of metabolism in rat and human microsomes was unaffected by the addition of the 1A inhibitor alpha-naphthoflavone.
Gene_expression (expressed) of CYP1A1 in 1A2
7) Confidence 0.67 Published 1997 Journal Xenobiotica Section Abstract Doc Link 9058530 Disease Relevance 0 Pain Relevance 0.04
We have identified a unique splice variant of CYP1A1 having deletion of 87 bp of exon 6 which is present in human brain but not in liver of the same individual.
Neg (not) Gene_expression (present) of CYP1A1 in brain
8) Confidence 0.63 Published 2006 Journal J. Neural Transm. Suppl. Section Abstract Doc Link 17017525 Disease Relevance 0.07 Pain Relevance 0.46
CYP1A1 is known as the classical target of the aryl hydrocarbon receptor (AhR).
Gene_expression (target) of CYP1A1
9) Confidence 0.62 Published 2007 Journal BMC Pharmacol Section Body Doc Link PMC2194763 Disease Relevance 0.05 Pain Relevance 0
Classical AhR ligands and, therefore, CYP1A1 inducers are hydrophobic and planar or coplanar molecules of polycyclic structure.
Gene_expression (inducers) of CYP1A1
10) Confidence 0.62 Published 2007 Journal BMC Pharmacol Section Body Doc Link PMC2194763 Disease Relevance 0 Pain Relevance 0
A strong upregulation was observed for CYP1A1, and, to a somewhat lesser extent, of CYP1B1.
Gene_expression (observed) of CYP1A1
11) Confidence 0.62 Published 2007 Journal BMC Pharmacol Section Body Doc Link PMC2194763 Disease Relevance 0.26 Pain Relevance 0
CYP1A1 protein was not detected in uncultured biopsies or explants.
Neg (not) Gene_expression (detected) of CYP1A1 protein
12) Confidence 0.59 Published 2001 Journal Toxicol. Sci. Section Abstract Doc Link 11452143 Disease Relevance 0.32 Pain Relevance 0.15
Indeed, Willey et al. (1996) were initially unable to detect CYP1A1 expression in alveolar macrophages, but upon application of more sensitive techniques these investigator were able to detect CYP1A1 gene expression (Willey et al. 1997).
Gene_expression (expression) of CYP1A1 in alveolar macrophages
13) Confidence 0.56 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1665420 Disease Relevance 0.43 Pain Relevance 0
Indeed, Willey et al. (1996) were initially unable to detect CYP1A1 expression in alveolar macrophages, but upon application of more sensitive techniques these investigator were able to detect CYP1A1 gene expression (Willey et al. 1997).
Gene_expression (expression) of CYP1A1 in alveolar macrophages
14) Confidence 0.56 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1665420 Disease Relevance 0.35 Pain Relevance 0
Expression of CYP1A1 (p < 0.01), CYP1B1 (p < 0.001), and CYP2S1 (p < 0.001) was higher in BAL cells from smokers compared with those of nonsmokers (Figure 1), whereas expression of CYP2B6/7 (p < 0.01) and CYP3A5 (p < 0.001) was lower; expression of CYP2A6/7, CYP2E1, CYP2C9, CYP2J2, and FMO5 was not altered.
Gene_expression (Expression) of CYP1A1 associated with nicotine addiction
15) Confidence 0.56 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1665420 Disease Relevance 0.65 Pain Relevance 0
In smokers, expression of CYP1A1 (p < 0.05), CYP1B1 (p < 0.001), and CYP2C9 (p < 0.05) was increased (p < 0.05) compared with non-smokers, and there was a trend toward increased expression of CYP3A5 (p = 0.0545; Figure 1); however, the expression of CYP2J2 was significantly (p < 0.05) repressed.
Gene_expression (expression) of CYP1A1 associated with nicotine addiction
16) Confidence 0.56 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1665420 Disease Relevance 0.84 Pain Relevance 0
The present study does, however, contradict the findings of Anttila et al. (1991), who did not find CYP1A1 expression in alveolar macrophages, regardless of smoking status.
Gene_expression (expression) of CYP1A1 in alveolar macrophages associated with nicotine addiction
17) Confidence 0.56 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1665420 Disease Relevance 0.25 Pain Relevance 0
Upon translocation into the nucleus, the AHR forms a heterodimer with its nuclear counterpart ARNT (AHR nuclear translocator) and drives gene expression of the AHR-responsible gene family, including CYP1A1 and CYP1B1 (Borlak and Thum 2001).
Gene_expression (expression) of CYP1A1 in nucleus
18) Confidence 0.56 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1665420 Disease Relevance 0.37 Pain Relevance 0
This may be due to different experimental approaches because Anttila et al. employed immunohistochemistry, whereas we used a sensitive RT-PCR method determine CYP1A1 and CYP1B1 expression and a fluorometric assay to demonstrate increased activity of the coded enzymes.
Spec (determine) Gene_expression (expression) of CYP1A1
19) Confidence 0.56 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1665420 Disease Relevance 0.24 Pain Relevance 0
These transformants are designated Hepc/1A1.4, Hepc/1A2.9, Hepc/2A6L.14, Hepc/2B6.68, Hepc/2C8.46, Hepc/2C9.1, Hepc/2C19.12, Hepc/2D6.39, Hepc/2E1.3-8 and Hepc/3A4.2-30, which stably expressed human CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4, respectively.
Gene_expression (expressed) of CYP1A1 in 1A2
20) Confidence 0.55 Published 2001 Journal Toxicol In Vitro Section Abstract Doc Link 11377097 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox